SMS Pharmaceuticals Limited (SMSPHARMA.NS)
INR 241.75
(1.64%)
INR 241.75
(1.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 498.26 Million INR | 805.82% |
| 2022 | -70.59 Million INR | -111.35% |
| 2021 | 622.19 Million INR | -0.49% |
| 2020 | 625.26 Million INR | 98.03% |
| 2019 | 315.73 Million INR | -21.16% |
| 2018 | 400.48 Million INR | 26.14% |
| 2017 | 317.49 Million INR | -22.64% |
| 2016 | 410.39 Million INR | 0.36% |
| 2015 | 408.92 Million INR | 16.02% |
| 2014 | 352.44 Million INR | 72.9% |
| 2013 | 203.84 Million INR | -19.51% |
| 2012 | 253.24 Million INR | 2126.36% |
| 2011 | 11.37 Million INR | -86.45% |
| 2010 | 83.92 Million INR | 250.37% |
| 2009 | 23.95 Million INR | -61.97% |
| 2008 | 62.98 Million INR | -76.81% |
| 2007 | 271.6 Million INR | 29.53% |
| 2006 | 209.68 Million INR | 146.47% |
| 2005 | 85.07 Million INR | 0.73% |
| 2004 | 84.46 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 164.79 Million INR | -4.63% |
| 2023 Q3 | 114.8 Million INR | -2.09% |
| 2023 FY | 498.26 Million INR | 805.82% |
| 2023 Q1 | 93.41 Million INR | 166.1% |
| 2023 Q2 | 117.25 Million INR | 25.51% |
| 2023 Q4 | 172.78 Million INR | 50.51% |
| 2022 Q1 | -127.66 Million INR | -299.2% |
| 2022 Q3 | 37.64 Million INR | 287.43% |
| 2022 Q4 | 35.1 Million INR | -6.74% |
| 2022 Q2 | -20.08 Million INR | 84.27% |
| 2022 FY | -70.59 Million INR | -111.35% |
| 2021 FY | 622.19 Million INR | -0.49% |
| 2021 Q2 | 230.27 Million INR | -2.27% |
| 2021 Q1 | 235.62 Million INR | 1.84% |
| 2021 Q3 | 89.62 Million INR | -61.08% |
| 2021 Q4 | 64.09 Million INR | -28.49% |
| 2020 Q1 | 70.27 Million INR | 9.93% |
| 2020 Q2 | 109.69 Million INR | 56.1% |
| 2020 FY | 625.26 Million INR | 98.03% |
| 2020 Q4 | 231.37 Million INR | 8.15% |
| 2020 Q3 | 213.93 Million INR | 95.03% |
| 2019 Q4 | 63.92 Million INR | -16.08% |
| 2019 Q1 | 77.67 Million INR | -42.05% |
| 2019 Q2 | 98.84 Million INR | 27.25% |
| 2019 Q3 | 76.17 Million INR | -22.94% |
| 2019 FY | 315.73 Million INR | -21.16% |
| 2018 FY | 400.48 Million INR | 26.14% |
| 2018 Q3 | 94.17 Million INR | -6.36% |
| 2018 Q2 | 100.57 Million INR | 40.29% |
| 2018 Q1 | 71.69 Million INR | 0.0% |
| 2018 Q4 | 134.04 Million INR | 42.33% |
| 2017 FY | 317.49 Million INR | -22.64% |
| 2016 Q2 | 113.22 Million INR | 23.71% |
| 2016 Q1 | 91.53 Million INR | -24.86% |
| 2016 FY | 410.39 Million INR | 0.36% |
| 2015 Q2 | 104.88 Million INR | 45.71% |
| 2015 Q3 | 110.24 Million INR | 5.11% |
| 2015 Q4 | 121.81 Million INR | 10.49% |
| 2015 FY | 408.92 Million INR | 16.02% |
| 2015 Q1 | 71.97 Million INR | -30.41% |
| 2014 Q1 | 81.83 Million INR | -25.24% |
| 2014 FY | 352.44 Million INR | 72.9% |
| 2014 Q4 | 103.43 Million INR | -10.62% |
| 2014 Q3 | 115.72 Million INR | 124.92% |
| 2014 Q2 | 51.45 Million INR | -37.13% |
| 2013 Q3 | 83.98 Million INR | 64.29% |
| 2013 Q4 | 109.46 Million INR | 30.34% |
| 2013 FY | 203.84 Million INR | -19.51% |
| 2013 Q2 | 51.11 Million INR | 225.53% |
| 2013 Q1 | -40.72 Million INR | -106.88% |
| 2012 FY | 253.24 Million INR | 2126.36% |
| 2012 Q2 | -135.05 Million INR | -335.88% |
| 2012 Q1 | -30.98 Million INR | -9.03% |
| 2012 Q3 | -173.07 Million INR | -28.16% |
| 2012 Q4 | 591.64 Million INR | 441.83% |
| 2011 FY | 11.37 Million INR | -86.45% |
| 2011 Q4 | -28.41 Million INR | -345.63% |
| 2011 Q3 | 11.57 Million INR | 0.0% |
| 2010 FY | 83.92 Million INR | 250.37% |
| 2009 FY | 23.95 Million INR | -61.97% |
| 2008 FY | 62.98 Million INR | -76.81% |
| 2007 FY | 271.6 Million INR | 29.53% |
| 2006 FY | 209.68 Million INR | 146.47% |
| 2005 FY | 85.07 Million INR | 0.73% |
| 2004 FY | 84.46 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott India Limited | 12.01 Billion INR | 95.852% |
| Cipla Limited | 41.21 Billion INR | 98.791% |
| Gland Pharma Limited | 7.72 Billion INR | 93.55% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.89 Billion INR | 91.554% |
| Kopran Limited | 509.56 Million INR | 2.218% |
| Marksans Pharma Limited | 3.13 Billion INR | 84.117% |
| NGL Fine-Chem Limited | 413.16 Million INR | -20.595% |
| Pfizer Limited | 5.51 Billion INR | 90.963% |
| Sanofi India Limited | 6.02 Billion INR | 91.736% |
| TTK Healthcare Limited | 628.41 Million INR | 20.712% |